Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of prophylaxis with BAY 81‐8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial

Published:2019-04-17 Issue:3 Volume:25 Page:
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Yang Renchi¹^ORCID,Sun Jing²,Zhao Yongqiang³,Wang Xuefeng⁴,Wu Depei⁵,Tseneklidou‐Stoeter Despina⁶,Wu Junde⁷,Church Nikki⁸^ORCID

Affiliation:

1. Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Tianjin China

2. Hematology Department, Nanfang Hospital Southern Medical University Guangzhou China

3. Peking Union Medical College Hospital Beijing China

4. Ruijin Hospital Shanghai China

5. First Affiliated Hospital of Suzhou University Suzhou China

6. Bayer Berlin Germany

7. Bayer Beijing China

8. Bayer Whippany New Jersey

Funder

Bayer

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13751

Reference19 articles.

1. Guidelines for the management of hemophilia

2. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

3. Meeting the challenges of haemophilia care and patient support in China and Brazil

4. Haemophilia care in China: achievements of a decade of World Federation of Hemophilia treatment centre twinning activities

5. The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients With Severe Hemophilia A: A Retrospective Analysis From the ReCARE Study

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of the B‐domain‐deleted TQG202 for on‐demand treatment in moderate and severe haemophilia A patients: A multicentre, single‐arm trial;Haemophilia;2023-03-13

2. A Comparison of the Incidence Rate for Joint Bleeding and FVIII Consumption between On-Demand versus Prophylaxis Factor VIII Replacement Therapy and the Direct Cost of Prophylaxis Treatment in Severe Haemophilia A Patients;Malaysian Journal of Medical Sciences;2023-02-28

3. The long‐term clinical benefits and economic costs associated with increased use of prophylaxis among patients with haemophilia A in China: Population‐based predictions from 2018 to 2033;Haemophilia;2022-06-17

4. Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B;Cochrane Database of Systematic Reviews;2021-08-18

5. Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review;Orphanet Journal of Rare Diseases;2021-06-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3